IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

"Antifungal Drug Selection In The Era Of Resistance: A Personalized And Pathogen – Specific Perspective"

1.Ms. Smital Sachin Gondkar, **2.** Vikas Kunde, **3.** Shruti Sanjay Joshi, **4.** Vishakha Prashant Patil, **5.** Ashwini Ramchandra Pagar.

1* Student, pravara college of pharmacy (for womens) chincholi, nashik, Maharashtra

2*Assistant Professor, pravara college of pharmacy (for womens) chincholi, nashik, Maharashtra

3*Student, pravara college of pharmacy (for womens) chincholi, nashik, Maharashtra

4*Student, pravara college of pharmacy (for womens) chincholi, nashik, Maharashtra

5*Student, pravara college of pharmacy (for womens) chincholi, nashik, Maharashtra

Abstract: Choosing the appropriate antifungal has become more difficult because of a rising number of invasive fungal infections and changing resistance patterns. This paper aims to provide insight into how pharmacokinetic properties, characteristics of the fungal organism, and patient-specific factors that affect the selection of appropriate antifungal agent. These variables can be narrowed down somewhat according to the susceptibility of particular fungi, the site of infection and pharmacokinetic factors eg, how well a drug reaches within infected tissues or its elimination from the body. Just as they are decisions about the activity of a drug in tumours, there are also factors which relate to the patient as an individual – immune status, renal and hepatic function, total body burdens and possibly other medications. Infections caused by resistant organisms like Candida glabrata and Aspergillus fumigatus call for susceptibility testing and informed treatment decisions. Additionally, the cost, availability, and required duration of treatment must be taken into account, particularly for long-term therapies. Results attributed to resistant Candida glabrata and Aspergillus fumigatus require susceptibility testing and informed therapeutic choices. The price is also being contemplated, in addition to accessibility and the necessary treatment time — which is particularly relevant for therapies over the long term. Overall, this review emphasizes the importance of a personalized, evidence-based approach to antifungal selection—one that not only improves treatment outcomes but also helps prevent toxicity and drug resistance

Index Terms: Antifungal drug, Invasive fungal, Antifungal resistance, Personalized therapy,

Introduction

Fungal infections are emerging as a major global health issue, especially among individuals with weakened immune systems—such as cancer patients, organ transplant recipients, or those living with HIV/AIDS. The rise in serious, invasive fungal infections combined with growing resistance to standard antifungal medications has made treatment selection more complex and critical than ever. Antifungal drugs—including azoles, polyenes, echinocandins, allylamines, and antimetabolites—each differ in how they work, the fungi they target, and how they behave in the body. Selecting the most appropriate drug requires a holistic assessment of several factors: the type and site of infection, the specific fungal species involved, its susceptibility profile, and the patient's immune condition, liver and kidney function, and risk for drug interactions.Gone are the days of one-size fits all antifungal therapy, as data from clinical and laboratory studies suggest that patients receiving directed therapy based on laboratory testing results or followed by standardized clinical guidelines receive more effective treatment. Timely intervention in antifungal therapy is critical with the emergence and spread of drug-resistant fungi such as Candida auris or azole-resistant Aspergillus.

This review aims to provide clinicians with a practical, comprehensive guide to selecting antifungal drugs—ensuring safer, more effective treatment strategies in an era of growing resistance



Skin Anatomy

The skin is not just our outer covering but it is the largest organ of our body, which make up around 16% of total body weight. Our skin serves as our outer barrier function, shielding us from infections, injuries and detrimental substances. In addition to a protective role, the skin helps regulate body temperature; supports sensory perception; plays a role in immune responses; and influences vitamin D production.

Layers of the Skin:

1.Epidermis

This is the outermost layer—thin, tough, and waterproof. It doesn't contain blood vessels and is made up of cells that provide a protective barrier.

2.Dermis

The layer of skin below the epidermis, it also contains structures like blood vessels, sweat glands, hair follicles and oil glands that are important for various functions.

3.Hypodermis (Subcutaneous Tissue)

The deepest layer and contains mostly fat, connective tissue. At the very least, it keeps you warm and gives your body some cushioning and fuel. Detailed View of layers:

a. **The Epidermis**

1.Stratum lucidum: Clear layer located in thick skin only (palms and soles)

2.Stratum spinosum: Cells in this layer are living and take on a starlike appearance._miss latte biologiametcalfe

3.Stratum granulosum: The cells in this layer have begun to produce keratin (a tough protective protein).miss_latte

4.Stratum granulosum: Water proofing **5.**

Stratum spinosum: Strengthen and flexibility.

6.Stratum basale: The very bottom, where new skin cells are made

Cells in the Epidermis:

Melanocytes: Produce melanin, which is the pigment that gives skin its color.

Langerhans cells: Assist the immune system to combat pathogens.

Merkel cells: involved in touch sensation

- **The dermis: two layers**

The papillary dermis:

Contains loose areolar connective tissue, capillaries, and sensory nerves.

Reticular dermis:

A deep layer of dense connective tissue rich in large collagen and elastin fibers which gives the skin its strength and pliability.

- **Includes :** Sweat and oil glands, blood vessels, hair follicles, lymphatics, and nerve endings.

Hypodermis (Subcutaneous Layer):

This is the body's insulation layer. It contains large blood vessels and fat, which aid in temperature regulation and cushioning against shocks.

Functions of the Skin:

1.Acts as a barrier to external threats (like germs and UV rays).

2.It regulates body temperature through sweating and circulation.

3.Allows sensations like touch, pressure, and pain.

4.Produces vitamin D when exposed to sunlight.

5.Plays a role in the immune system with built-in defenses.

Diseases Caused by Fungal Infections and Their Causative Organisms

Fungal infections, or mycoses, can vary from mild skin issues to serious, life-threatening diseases. These infections are typically grouped based on how deep they affect the body and the type of fungi involved.

1. Superficial Mycoses

These infections affect only the outermost layers of the skin, hair, or nails and usually don't trigger inflammation.

Disease Causative Fungus Notable Features

Tinea versicolor: Malassezia furfur, leads to discolored patches on the chest or back with mild itching.

Black Piedra : Piedraia hortae, results in hard black nodules forming on hair shafts.

White Piedra : Trichosporon beigelii , White soft nodules on scalp or beard hair.

2. Cutaneous Mycoses

These involve deeper layers of the skin, as well as hair and nails. The fungi responsible are called dermatophytes and feed on keratin.

Disease (Tinea) Causative Fungi (Dermatophytes) Key Characteristics :

Tinea capitis: Microsporum or Trichophyton, hair loss may be seen with a scalp infection.

Tenia pedis: Trichophyton rubrum Cracked itchy feet (Athlete´s foot) Jock itch.

Tinea cruris : Epidermophyton floccosum Skin and pus/onychomycosis of toenail.

Tinea unguium : Trichophyton rubrum Thick, discolored toenails or fingernails.

3. Subcutaneous Mycoses

These infections occur when fungi enter the body through cuts or wounds and affect deeper skin layers and connective tissues.

Disease Causative Fungus Key Features:

Sporotrichosis : Sporothrix schenckii Nodules along lymphatic channels.

Chromoblastomycosis : Fonsecaea, Cladosporium Warty, cauliflower-like skin growths.

Mycetoma (Madura foot) : Madurella spp. Swelling, pus-filled sinuses, and visible granules.

4. Systemic (Endemic) Mycoses

These primarily affect the lungs when spores are inhaled but can spread to other organs. They can affect both healthy and immunocompromised individuals.

Disease Causative Fungus Key Features

1.Histoplasmosis: Histoplasma capsulatum Mimics tuberculosis, starts in lungs.

2.Blastomycosis: Blastomyces dermatitidis involving the lungs, skin and bones.

3.Coccidioidomycosis: Coccidiodies immitis (Valley Fever – "San Joaquin valley fever")/chest pain.

4.Paracoccidioides brasiliensis :Chronic oral ulcers, lingual nodules.

5. Opportunistic Mycoses

These typically infect people with compromised immune systems, like those in ICUs or patients with HIV or on chemotherapiy.

Disease Causative Fungus Clinical Features:

Candidiasis : Candida albicans Oral thrush, vaginal infections, or bloodstream sepsis.

Aspergillosis : Aspergillus fumigatus Lung "fungus balls" or invasive lung disease.

Cryptococcosis: Cryptococcus neoformans Meningitis, especially in HIV-positive patients.

Mucormycosis (black fungus) : Rhizopus, Mucor Rapid tissue destruction in sinuses and brain.

Pneumocystis pneumonia (PCP) : Pneumocystis jirovecii Severe pneumonia common in AIDS patient.

Classification of Antifungal Drugs

Antifungal medications are grouped based on how they work, their chemical structure, and the types of fungal infections they treat. Knowing their differences helps healthcare providers choose the right one for each patient.

Drug Class with Examples and How It Works (Mechanism of Action)

Polyenes: Amphotericin B, Nystatin which Bind to ergosterol in fungal membranes, forming holes → fungal cell leaks and dies.

Azoles : Fluconazole, Itraconazole, Voriconazole Block an enzyme (lanosterol 14α-demethylase) → stops ergosterol production, weakening the membrane.

Echinocandins: Caspofungin, Micafungin which Inhibit β-1,3-glucan synthesis, an essential part of the fungal cell wall.

Allylamines : Terbinafine which Block squalene epoxidase, preventing ergosterol production.

Antimetabolites : Flucytosine it Converted into 5-FU inside fungal cells → interferes with DNA and RNA synthesis.

New Generation Antifungal Drugs:

New Class with Example and Mechanism of Action

Triterpenoids (Ibrexafungerp) which Also inhibits β-glucan synthesis like echinocandins but taken orally.

New Antifungal Drugs – Modern Tools Against Resistant Fungi

With older antifungal drugs becoming less effective due to rising resistance, researchers have developed new antifungals that are safer, easier to take, and more powerful—especially against resistant fungi.

1. Ibrexafungerp (Brand name: Brexafemme)

What It Is: First oral antifungal in a new class called triterpenoids

How It Works: Inhibits β-1,3-D-glucan synthase (essential for fungal cell wall)

Targets: Most Candida species, including azole-resistant strains

FDA Approved: Yes (2021–2023) for vaginal and invasive candidiasis

2. Rezafungin

What It Is: A long-acting echinocandin

Unique Feature: Only needs once-weekly dosing due to long half-life

How It Works: Inhibits glucan synthesis in fungal cell walls

Targets: Candida, Aspergillus species

FDA Approved: Yes (2023) – especially useful for hospitalized patients

3. Fosmanogepix

What It Is: A first-in-class antifungal with a novel mechanism

How It Works: Blocks GPI-anchor biosynthesis via Gwt1 protein inhibition

Targets: Resistant Candida auris, Aspergillus, and rare molds

Clinical Trials: In advanced (Phase II/III) stages

4. Olorofim

What It Is: Belongs to a brand-new class: Orotomides

How It Works: Inhibits DHODH enzyme → disrupts fungal DNA building

Targets: Mold infections including Aspergillus, Scedosporium, Lomentospora

Clinical Status: Phase III trials; used in resistant mold infections

5. VT-1598

What It Is: A newer tetrazole antifungal

Why It's Better: Selectively targets fungal enzymes, making it safer for patients

Targets: Endemic fungi include Histoplasma, Blastomyces and Coccidioides.

Trial Status: In Phase II

6. MAT2203

What It Is: An oral version of Amphotericin B

Formulation: Lipid-based encochleated capsule (less toxic)

Targets: Cryptococcus, Candida, Aspergillus

Trial Status: Phase II

Why It's Special: Offers oral delivery with reduced kidney toxicity

7. ATI-2307

What It Is: A promising arylamidine derivative

How It Works: Disrupts mitochondrial membrane potential in fungi

Targets: Cryptococcus (especially meningitis), Candida, Aspergillus

Trial Status: Early clinical phases (Phase I/II)

Routes of Administration – How Antifungals Are Given :

Topical : Clotrimazole cream and miconazole gel are used to treat mild infections of the skin, nails, or mucous membranes.

Oral (by mouth) : Mild to moderate internal or mucosal infections Fluconazole tablets, Terbinafine tablets.

Intravenous (IV) : Serious or deep infections (e.g. brain, lungs, blood) Amphotericin B, Caspofungin, Micafungin.

Example:

Fluconazole can treat fungal meningitis as it penetrates the brain effectively.

Echinocandins are only given by IV because they don't absorb well orally.

- **Common Antifungal Drugs and Their Side Effects**

Drug/Class Common Side Effects -

Amphotericin B : may cause Kidney damage (nephrotoxicity), along with fever and chills, often referred to as the "shake and bake" reaction.

Azoles : Liver toxicity, nausea, drug interactions, heart rhythm issues (QT prolongation).

Echinocandins : Generally well-tolerated; rare infusion-related reactions or mild liver enzyme elevations.

Flucytosine : Bone marrow suppression (low blood cells), nausea, vomiting, diarrhea.

Reasons for Side Effects -

Fungal cells and human cells share some biological similarities, especially in membrane composition.

This makes it hard to kill fungi without affecting the human body too.

For example, azoles interfere with ergosterol (fungal cholesterol-like substance), but also affect human cholesterol pathways.

- **Drug-Drug Interactions – Particularly with Azoles :**

Azoles interfere with the liver's enzyme system (CYP450), which is also used to process many other medications. This can cause:

Toxic build-up of other drugs

Reduced effectiveness of antifungals

Increased risk of side effects from other medications

- **Antifungal drug selection :-**

Invasive fungal infections

Antifungal resistance

Personalized therapy

Evidence-based treatment

- **Antifungal Resistance – What It Is and Why It Matters**

Just like bacteria, fungi can become resistant to the medications meant to kill them. This means the drug no longer works effectively, and infections become harder to treat. Antifungal resistance is a growing global concern, especially in hospitals and among immunocompromised patients.

- **Fungi Showing Major Resistance:**

Candida auris : Fluconazole, Amphotericin B, even echinocandins

Candida glabrata : Azoles (e.g. fluconazole), some echinocandins

Aspergillus fumigatus : Azoles (e.g. itraconazole, voriconazole)

These species are particularly worrisome because they can spread in hospitals and cause life-threatening bloodstream, brain, or lung infections.

- **How Fungi Develop Resistance: Key Mechanisms**

Efflux Pumps:

The fungus "pumps out" the drug before it can act inside the cell.

Target Site Mutations:

The drug target changes shape, so the drug can no longer bind effectively.

Biofilm Formation:

Some fungi form biofilms—a slimy shield—that prevents drugs from penetrating.

Metabolic Adaptation:

Fungi alter their metabolism so they can survive even without the pathway the drug is targeting.

- **Why Resistance Is Dangerous**:

It limits treatment options—especially for critical cases.

Patients may not respond to first-line therapy, delaying recovery.

Doctors may need to use more toxic or less effective alternatives.

It increases the risk of complications, hospitalization, and death.

- **Factors That Drive Resistance:**

Overuse or misuse of antifungals (especially in agriculture and medicine)

Inadequate dosing

Long-term therapy without proper monitoring

Delayed diagnosis and inappropriate treatment choices

➢ **Clinical Takeaway:**

Always confirm the fungal species and its susceptibility.

Choose antifungals based on lab results whenever possible.

Monitor response and switch treatment early if resistance is suspected.

☆ New and Emerging Fungi – Rising Threats in Antifungal Resistance

In recent years, new fungal species have begun to appear that are more difficult to diagnose and even harder to treat. Many of these fungi are resistant to multiple drugs, spread easily in hospitals, and are often mistaken for other infections.

1. Candida auris

First Identified: 2009 in Japan

Why It's Concerning:

Highly resistant to multiple drugs (including azoles, echinocandins, Amphotericin B)

Difficult to detect with standard lab methods

Can survive on hospital surfaces and cause outbreaks

Clinical Impact: Causes severe bloodstream infections; high mortality rates

Treatment Progress:

New drugs like Ibrexafungerp, Rezafungin, and Fosmanogepix show promise

Rapid diagnostic and surveillance programs are improving worldwide

2. Aspergillus lentulus

Related To: Aspergillus fumigatus

Why It's Concerning:

Looks similar to A. fumigatus but is more resistant to azoles

Clinical Impact: Found in lungs/sinuses of immunocompromised patients; causes invasive pulmonary aspergillosis

Treatment Progress:

Requires advanced molecular tests for detection

Responds to newer antifungals like Olorofim

3. Emergomyces species

Found In: South Africa, India, Europe

Type: Dimorphic fungi (mold in environment, yeast in body)

Clinical Impact:

Causes skin and lung infections, especially in HIV patients

Often mistaken for tuberculosis or histoplasmosis

Treatment: Amphotericin B, followed by azoles

4. Scedosporium & Lomentospora prolificans

Found In: Soil, sewage, polluted water

Why It's Concerning:

Extremely resistant—even to Amphotericin B

Clinical Impact: Brain abscesses, sinus and bone infections

Treatment Progress:

Responds only to investigational drugs like Olorofim

Often needs combination therapy

5. Fusarium species

Can Cause: Eye infections (keratitis) and widespread infections in neutropenic patients

Why It's Concerning:

Increasing resistance to both azoles and polyenes

Treatment Progress:

Diagnosis via histology or PCR

Limited treatment options; ongoing trials with Fosmanogepix

6. Trichophyton indotineae

Previously Known As: T. mentagrophytes genotype VIII

IN Discovered In: India (major outbreaks reported)

Why It's Concerning:

Causes chronic ringworm (tinea) infections

Resistant to terbinafine, the usual treatment

Clinical Impact: Spreads via skin contact or contaminated items

* Treatment Progress:

Oral itraconazole preferred

Surveillance programs are critical to prevent spread

- **Host Factors** – How the Patient's Immune System Affects Fungal Infections

Not everyone is at equal risk when it comes to fungal infections. A person's immune system plays a huge role in determining:

1. Immunocompetent Hosts

(People with healthy immune systems)

Their immune defenses are strong enough to fight off most fungal infections.

They may still get mild infections like:

Ringworm (Tinea)

Oral or vaginal yeast infections (Candida)

Tinea versicolor (Malassezia)

Sporotrichosis (via minor skin trauma

2. Immunocompromised Hosts

(People with weakened or suppressed immunity)

These patients are at much higher risk of getting serious or life-threatening fungal infections. Let's look at some common high-risk groups:

- Patient Group and Why They're at Risk with Common Infections
  1. **HIV/AIDS** : Low CD4 T cells weaken immune response, Cryptococcal meningitis, Candidiasis, Histoplasmosis
  2. **Cancer patients** (e.g., leukemia) : Chemotherapy suppresses immune system, Invasive Candidiasis, Aspergillosis
  3. **Organ transplant recipients** : On immunosuppressive drugs to prevent rejection, Aspergillosis, Candidiasis
  4. **Bone marrow/stem cell transplant** : cause severe immune suppression during and after the procedure, increasing the risk of Invasive fungal infections.
  5. **Uncontrolled diabetics :** Poor neutrophil function, Mucormycosis (black fungus), Candidiasis
  6. **ICU patients** (especially ventilated) : Weak immunity, hospital environment, broad antibiotics and also infected by Candida auris, Aspergillosis
  7. **Long-term steroids/antibiotic use :** Alters immune balance and gut flora Candidiasis, Mucormycosis
  8. **Premature or low birth-weight babies :** Immature immune system, Neonatal Candidiasis

In high-risk patients, prevention and early diagnosis are just as important as treatment.

- Pharmacokinetics & Pharmacodynamics of Antifungal Drugs – How They Work and Travel in the Body

To treat fungal infections effectively, it's essential to understand two things:

Pharmacodynamics (PD): What the drug does to the fungus.

Pharmacokinetics (PK): How the body processes a drug.

- **Pharmacodynamics (PD) – The Drug's Action on Fungi**

Different antifungal drugs target different parts of the fungal cell, either weakening it or killing it outright.

Drug Class with it's Target and Effect on the Fungus

Azoles : Enzyme: Lanosterol 14α-demethylase, Blocks ergosterol production → weakens fungal membrane

Polyenes : Ergosterol in fungal membrane, Binds to it → creates holes → cell leaks and dies

Echinocandins : Enzyme: β-1,3-glucan synthase, Weakens the fungal cell wall (not membrane) → cell rupture

Allylamines : Enzyme: Squalene epoxidase, Prevents ergosterol synthesis → buildup of toxic squalene

Flucytosine : transformed into 5-FU within the cell, where it blocks DNA and RNA production,preventing fungal growth.

- **Pharmacokinetics (PK) – How Antifungals Move in the Body**

PK involves ADME – Absorption, Distribution, Metabolism, and Excretion.

Steps with examples

Absorption : How well the drug is absorbed into the blood, Fluconazole is well-absorbed orally; Nystatin is not (used only topically)

Distribution : How the drug spreads in the body Amphotericin B reaches almost all organs; Fluconazole enters the brain

Metabolism : How a drug is broken down, usually in the liver; azoles undergo liver metabolism, so they should be used carefully in the liver disease.

Excretion : process of eliminating a drug from the body- fluconazole is removed through the kidneys, while itraconazole is excreted in bile.

- **Treatment of Fungal Infections**

Matching the Drug to the Fungus and the Site

Fungal infections vary greatly—from minor skin issues to deadly brain or bloodstream infections. Right treatment depends upon :

The type of fungus:

The site of infection (skin, lungs, blood, brain)

Skin Infections (Tinea / Ringworm)

Fungus: Trichophyton, Microsporum

Treatment: Topical terbinafine or clotrimazole

Severe Cases: Oral terbinafine for 2–4 weeks

1. **Vaginal Candidiasis**

Fungus: Candida albicans

Treatment: Oral fluconazole or clotrimazole cream

If Pregnant: Topical options are preferred

2. **Oral Thrush**

Fungus: Candida albicans

Treatment: Nystatin mouthwash or oral fluconazole

3. **Invasive Candidiasis (Bloodstream or Deep Organ Infections)**

Fungus: Candida spp.

Treatment: Echinocandins (e.g., caspofungin) or fluconazole

4. **Cryptococcal Meningitis**

Fungus: Cryptococcus neoformans

Treatment Plan:

Induction: Amphotericin B + Flucytosine

Maintenance: Fluconazole for several weeks

5. **Aspergillosis (Lung Infections)**

Fungus: Aspergillus fumigatus

First-Line: Voriconazole

Second-Line: Amphotericin B

6. **Mucormycosis (Black Fungus)**

Fungus: Mucor, Rhizopus

Treatment: Liposomal Amphotericin B, followed by Posaconazole

Often Requires: Surgical removal of infected tissue

7. **Histoplasmosis (Lung/Systemic Infection)**

Fungus: Histoplasma capsulatum

Treatment:

Mild: Itraconazole

Severe: Amphotericin B

8. **Nail Infections (Tinea unguium / Onychomycosis)**

Fungus: Trichophyton rubrum

Treatment: Oral terbinafine for 6–12 week

- Fungal Resistance – Causes, Consequences, and How to Fight It :

Fungi, similar to bacteria, can gradually become resistant to medications This can make the treatment less effective, the infections more difficult to deal with and the tools available for doctors more limited.

9. What Is Antifungal Resistance?

Resistance happens when a fungus either shifts or adapts so that it can survive in the presence of antifungal drugs. This can make infections that are more difficult to manage because common treatments may no longer work.

10. Examples of Resistant Fungi and Their Challenges:

Fungus Drug Resistance Why It's a Problem

Candida auris: Fluconazole, Amphotericin B, even Echinocandins, Multidrug-resistant; spreads in hospitals

Candida glabrata: Fluconazole, some Echinocandins, Rapid resistance mutations; common in ICU infections

Aspergillus fumigatus : Azoles (e.g., voriconazole, itraconazole), Long-term azole use leads to environmental resistance

Trichophyton indotineae: Terbinafine, Causes widespread treatment failures in ringworm cases

Cryptococcus neoformans: Fluconazole (high-dose or prolonged use), Particularly in HIV/AIDS patients

Mucorales species: Most azoles (except posaconazole, isavuconazole) Naturally resistant; aggressive in diabetic patients

- **How Do Fungi Become Resistant?**

Mutations – Changes in target enzymes mean drugs can't bind effectively.

Efflux Pumps – Fungi pump the drug out before it can act.

Biofilm Formation – Fungi form protective layers that block drug penetration.

Drug Overuse – Repeated exposure selects for resistant strains.

- **Why This Is Dangerous**:

Treatment fails or is delayed

Higher risk of complications or death

Doctors must resort to more toxic or expensive drugs

Hospital outbreaks become harder to control

- **How to Fight Antifungal Resistance:**

Strategy of why does it help –

Correct diagnosis (culture, PCR, etc.), Ensures the right fungus is targeted

Using the correct drug at the proper dose helps prevent underdosing and reduces the risk of resistance

Avoid overuse Reduces pressure on fungi to mutate

Use combination therapy when needed

More effective and reduces resistance development

Monitor resistance trends helps guide regional and global treatment guidelines

- **Personalized & Evidence-Based Antifungal Therapy – Tailoring Treatment to the Patient**

In today's world of rising drug resistance and complex fungal infections, a "one-size-fits-all" approach no longer works. Instead, doctors now use a personalized, evidence-based strategy to choose the best antifungal treatment.

11. What Does This Mean?

Based on evidence : Use of published guidelines, clinical trials and FAuc data to choose the best feasible medicine.

Specific to the individual Patient-specific Adapting that treatment to a patient with a unique presentation and immune status, with infection at specific anatomic sites and risk factors

12. Evidence-Based Medicine (EBM) in Action:

Doctors rely on scientific data to guide choices.

Examples:

Choosing voriconazole over Amphotericin B for Aspergillus based on higher survival in trials

Using echinocandins for Candida infections in ICUs with known fluconazole resistance

EBM = Right drug, right situation, backed by science

13. Personalized Medicine Factors:

Patient Factor and why It Matters -

Immune status Immunocompromised patients need stronger treatments

Infection location: Brain vs. skin vs. lungs require different drugs

Fungal species: Determines sensitivity/resistance

Organ function: Liver/kidney issues can limit drug options

Pregnancy status: Some drugs are unsafe during pregnancy

Previous drug exposure: Prior antifungal use can increase resistance risk

- **Case-Based Examples:**

Patient Personalized Strategy -

1. Diabetic with mucormycosis Start early with liposomal Amphotericin B; monitor kidney function; surgery may be needed
2. ICU patient with Candida auris Use echinocandins due to high resistance to fluconazole and Amphotericin B
3. Pregnant woman with vaginal yeast Prefer topical clotrimazole over oral fluconazole (oral azoles may pose risk during pregnancy)

14. Why This Approach Works:

Reduces treatment failure

Avoids unnecessary toxicity

Prevents development of resistance

Improves recovery and patient outcomes

Conclusion

Today it is not sufficient to select an anti-fungal in order to treat a fungal infection: the use of any drug requires a considered, individualized approach. Due to increasing prevalence of drug-resistant fungi such as Candida auris and Aspergillus fumigatus, doctors need a broader spectrum therapy. They have to take into account what type of fungus it is, where it lives in the body, how well the drug works against all those types of factors and in the patient's system.

However, new antifungal medicines including ibrexafungerp and olorofim — provide fresh optimism for treating such intractable infections. However, there is a catch — using these drugs well requires integrating active clinical guidance, while monitoring and adjusting treatments based on resistance patterns to provide the right treatment regimen for each individual patient.

In other words, although good old amphotericin B still treats many broad-span Candida and Aspergillus isolates today, there is no one-size-fits-all antifungal therapy payoff these days. Personalized sepsis treatment—tailored to patient genetic profile using the type-specific results of the research described here—can improve recovery and decrease side effects and prevent drug resistance in future strains. This is not only a more humane form of treatment it is the smarter and safer path for our future.

References

1. Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update. Clin Infect Dis. 2016;62(4):e1–50.
2. Perfect JR. The antifungal pipeline: a reality check. Nat Rev Drug Discov. 2017;16(9):603–16.
3. Wiederhold NP. Emerging fungal infections: new drugs and new targets. Expert Opin Emerg Drugs. 2021;26(3):199–212.
4. Thompson GR, Wiederhold NP, Fothergill AW. Rezafungin and other new antifungal agents for invasive infections. J Fungi. 2021;7(10):847.
5. Hoenigl M, et al. The potential role of olorofim in the treatment of invasive

fungal infections. Clin Microbiol Rev. 2023;36(1):e00142-21.
6. Andes D, van Ogtrop M. Characterization and quantitation of the pharmacodynamics of fluconazole in a murine model of disseminated candidiasis. J Infect Dis. 2000;182(2):564–70.
7. Moriyama B, Henning SA, Leung J, et al. Adverse effects associated with systemic antifungal therapy. Pharmacotherapy. 2014;34(8):794–806.
8. Cowen LE, Sanglard D, Howard SJ, Rogers PD, Perlin DS. Mechanisms of antifungal drug resistance. Cold Spring Harb Perspect Med. 2015;5(7):a019752.
9. Chowdhary A, Sharma C, Meis JF. Candida auris: A rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally. PLoS Pathog. 2017;13(5):e1006290.
10. Lockhart SR. Candida auris and multidrug resistance: Defining the new normal. Fungal Genet Biol. 2019;131:103243.
11. Arendrup MC, Patterson TF. Multidrug-resistant Candida: Epidemiology, molecular mechanisms, and treatment. J Infect Dis. 2017;216(suppl_3):S445–51.
12. Verweij PE, Chowdhary A, Melchers WJ, Meis JF. Azole resistance in Aspergillus fumigatus: Can we retain the clinical use of mold-active antifungal azoles? Clin Infect Dis. 2016;62(3):362–8.
13. Ghannoum MA, Rice LB. Antifungal agents: Mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev. 1999;12(4):501–17.
14. Odds FC, Brown AJ, Gow NA. Antifungal agents: mechanisms of action. Trends Microbiol. 2003;11(6):272–9.
15. Hope WW, Drusano GL, Moore C, et al. Pharmacodynamics of antifungal drugs: Practical insights for clinical use and future research. Curr Opin Infect Dis. 2009;22(6):574–80.
16. Petraitis V, Petraitiene R, Walsh TJ. Targeting the fungal cell wall: The antifungal activity of echinocandins. Expert Opin Investig Drugs. 2001;10(10):1747–58.
17. Benedict K, Jackson BR, Chiller TM, Beer KD. Estimation of direct healthcare costs of fungal diseases in the United States. Clin Infect Dis. 2019;68(11):1791–7.
18. Fisher MC, Hawkins NJ, Sanglard D, Gurr SJ. Worldwide emergence of resistance to antifungal drugs challenges human health and food security. Science. 2018;360(6390):739–42.
19. Wiederhold NP. The antifungal arsenal: alternative drugs and future targets. Int J Antimicrob Agents. 2018;51(3):333–9.
20. Pfaller MA, Messer SA, Rhomberg PR. Activity of ibrexafungerp against clinical isolates of Candida and Aspergillus species, including echinocandin- and azole-resistant strains. J Antimicrob Chemother. 2021;76(4):1085–90.
21. Mellinghoff SC, Cornely OA, Koehler P. Personalized antifungal therapy—are we there yet? Pharmacol Res Perspect. 2020;8(1):e00554.
22. Zhai B, Zhu P. Towards personalized antifungal therapy: Predicting patient outcomes with systems biology and pharmacogenomics. Front Pharmacol. 2022;13:857421.
23. Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Global guideline for the diagnosis and management of rare mold infections: an initiative of the ECMM in cooperation with ISHAM and ASM. Lancet Infect Dis. 2020;21(8):e246–57.
24. Ullmann AJ, Aguado JM, Arikan-Akdagli S, et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect. 2018;24:e1–38.